Thursday, June 11, 2026

Intelligence Β· INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,797
Companies 1,769
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Showing page 120 of 200 Β· By data quality, then INN

  1. clesrovimab

    ENFLONSIA

    EMA: approved

    J06BD10
  2. clostridium botulinum, serotype e, neurotoxin (150 kda)

    BOEY

    EMA: unknown

    M03AX01
  3. cobimetinib

    COTELLIC Hoffmann-La Roche

    EMA: approved Β· TGA: approved

    L01XE38
  4. colesevelam

    CHOLESTAGEL

    EMA: approved

    C10AC04
  5. colestilan

    BINDREN

    EMA: withdrawn

    V03AE
  6. concentrate of proteolytic enzymes enriched in bromelain

    NEXOBRID

    EMA: approved

    D03BA03
  7. conestat alfa

    RUCONEST

    EMA: approved

    B06AC04
  8. copanlisib

    ALIQOPA

    EMA: application withdrawn

  9. copper (64cu) chloride

    CUPRYMINA

    EMA: approved

    Not yet assigned
  10. copper (64cu) oxodotreotide

    DEQTYNET

    EMA: unknown

    V09IX15
  11. corifollitropin alfa

    ELONVA Organon Pharma Pty Ltd

    EMA: approved Β· TGA: approved

    G03GA09
  12. covid-19 vaccine (ad26.cov2-s [recombinant])

    JCOVDEN (PREVIOUSLY COVID-19 VACCINE JANSSEN)

    EMA: withdrawn

    J07BN02
  13. covid-19 vaccine (chadox1-s [recombinant])

    VAXZEVRIA (PREVIOUSLY COVID-19 VACCINE ASTRAZENECA)

    EMA: withdrawn

    J07BN02
  14. covid-19 vaccine (inactivated, adjuvanted, adsorbed)

    COVID-19 VACCINE (INACTIVATED, ADJUVANTED) VALNEVA

    EMA: withdrawn

    J07BX03
  15. covid-19 vaccine (recombinant, adjuvanted)

    BIMERVAX

    EMA: approved

    J07BN
  16. crizanlizumab

    ADAKVEO

    EMA: unknown

    B06AX01
  17. crovalimab

    PIASKY

    EMA: approved Β· PMDA: approved

    L04AJ07
  18. dabrafenib

    TAFINLAR Novartis Pharmaceuticals

    EMA: approved Β· TGA: approved Β· NMPA: clinical trials

    L01EC02
  19. daclatasvir

    DAKLINZA

    EMA: unknown

    J05AP07
  20. dalbavancin

    XYDALBA

    EMA: approved

    J01XA04
  21. damoctocog alfa pegol

    JIVI

    EMA: approved Β· PMDA: approved

    B02BD02
  22. dantrolene sodium, hemiheptahydrate

    AGILUS

    EMA: approved

    M03CA01
  23. daridorexant

    QUVIVIQ

    EMA: approved Β· NMPA: clinical trials

    N05CJ03
  24. dasabuvir

    EXVIERA

    EMA: withdrawn

    J05AP09

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles β€” INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page β€” it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.